Workshop: Overcoming the Challenges of Commercializing in Europe

  • Written by admin
  • December 13, 2012 at 10:02 pm
  • Case studies with industry leaders exploring regulatory, market opportunity and creative financing

    Tuesday, January 8th: 2:15PM – 3:10PM

    This session features three CEO’s currently involved with companies that are commercialized in Europe. This interactive roundtable is designed to cover main themes for product growth in Europe, as well as analysis of particular key developmental milestones. Topics explored include:

    Strategy:
    Why Europe today — Market Expectations, and how to navigate cost, time and resources

    Financial:
    Creative Funding, the Best use of resources in today’s market, and realistic objectives

    Regulatory:
    Clinical trials, Key opinion leaders, geography, and time to market

    Reimbursement:
    Where and when, time savers, and navigating the system

    The workshop will also explore reaching short-term milestones upon commercialization, including:

    • Shotgun or rifle approach?
    • Direct vs. Distributor
    • Partnership opportunities

    Faculty:

    Rick Hughes, President, HealthLink Europe, has been in the medical device industry for 18 years, and joined HealthLink Europe in February 2005. During the first year of his tenure, HealthLink Europe secured funding from a private investment firm, opened a North American Office, and invested in top quality management and IT systems, to support the future growth of the company. Mr. Hughes became President of HealthLink Europe in December 2005 and since then the company has grown significantly each year providing operational support for more than 50 medical device manufacturers in Europe. Before joining HealthLink Europe, Mr. Hughes was Vice President of Client Development for TriVirix, an FDA registered contract manufacturer of electronic and electro- mechanical medical devices, from February 2000, to January 2005. During this time TriVirix achieved rapid annual growth, supporting medical device manufacturers in America and the UK. Prior to joining TriVirix, Mr. Hughes spent six years with Vernacare, a UK based hospital equipment and disposables manufacturer, where he became an Account Director in North America. Mr. Hughes holds a Bachelor of Arts degree from Oxford Brookes University in the UK.

    Gibb Clarke, co-founder and CEO of Blockade Medical, has more than 10 years experience as a medical device executive with a specific focus on new technology development for the interventional neurovascular marketplace. Prior to co-founding Blockade, Gibb co-founded Pulsar Vascular, Inc. in 2006. A novel therapeutic approach for challenging and complex cerebral aneurysms. Gibb successfully raised multiple rounds of venture capital as well as helped craft and manage the clinical and regulatory strategy for both CE Mark and US approvals. Prior to Pulsar, Gibb played a critical early role in helping Swedish Medical Center in Seattle, WA, plan for and execute the development of The Seattle Neuroscience Institute, a neuroscience center for excellence. Gibb’s efforts resulted in Swedish Medical investing in excess of $35M into the development of its now flagship neuroscience center located in Seattle, WA. Gibb also spent 8 years in the US Marines Corps serving as a team leader in the elite Marine Recon unit. Military schoolings include Amphibious Recon Course, Army Ranger School, US Navy Dive School, and Army Jump School. Gibb is an avid endurance athlete, having competed in over 200 races.

    Greg Lambrecht, Founder and Executive Director of Intrinsic Therapeutics, Inc, a venture-backed medical device company focused on addressing the needs of patients with spinal disorders. Mr. Lambrecht is also founder and board member of Viacor, Inc., a start-up medical device company, and Coravin, LLC, a consumer product company, both in the Boston area. Prior to this, Mr. Lambrecht was Vice President of Product Development & Marketing at Stryker, a global orthopedic implant company where he directed the development and launch of numerous successful orthopedic implants. Mr. Lambrecht also held various management positions in product development, marketing, and business development within Pfizer’s Medical Technology Group. The core of his career at Pfizer was directed at implementing a process for inventing and developing technologies that best met the needs of Pfizer’s physician customers worldwide. Mr. Lambrecht holds a Masters of Science in Mechanical Engineering and a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology. He holds numerous patents in the fields of gynecology, general surgery, cardiology, and orthopedics.

    Paul Geudens, founder and CEO of Quarterback Consulting. Quarterback Consulting’s mission is to provide executive support to US based Cardiovascular Device startups in their (pre)-commercialization into Europe, the latest being Surpass Medical that was recently acquired by Stryker for $135M. Paul is a senior executive holding a unique blend of medical, commercial and business development experience. Paul started his career in ’81 as head of the Department of Interventional Cardiology at the University Hospital of Antwerp, Belgium. In 1988, Paul made the move to the Medical Device industry and held roles of increasing responsibility at Baxter, BOC UK and, from 1997 till 2009, at Cordis Johnson and Johnson. At Cordis, he was responsible for the launch of the company’s blockbuster BMS and DES coronary stents, the development of the Neurovascular business and for their leadership in the highly competitive Endovascular market. In 2009, Paul made his entry into the medical device startup environment as Vice President of Sales and Marketing at Stentys SAS, Paris, France. After 1 year of highly successful commercial activity under Paul’s leadership, the company went into an IPO and raised $31.9M at the NYSE Euronext Paris Stock Exchange. Paul founded Quarterback Consulting early 2012. In his role as Executive Consultant to Surpass Medical, he has been instrumental in creating company value that led to the before mentioned successful acquisition. With Quarterback Consulting, Paul is further developing and refining effective EU commercial entry strategies that apply to a number of current and future Medical Device clients. Paul holds a BSc in Radiography and Hospital Management and an ADP at London Business School.

  • Conference Info:

     

    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City


    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!